Herpes simplex virus mutants PAAr5, AraAr6, AraAr7, AraAr9, and AraArl3, which previously had been shown to be resistant to arabinosyladenine (araA) alone, were found to be resistant to araA in the presence of high concentrations of the adenosine deaminase inhibitor, deoxycoformycin. The marker conferring resistance to araA and deoxycoformycin in mutant PAAr5 was mapped finely to an 0.8-kilobase-pair region in the herpes simplex virus DNA polymerase locus. These results indicate that the mutants are resistant to araA itself rather than to its deamination product and confirm the importance of the viral polymerase in the antiviral action of araA.
Arabinosyladenine (9-p-D-arabinofuranosyladenine, vidarabine, adenine arabinoside, ViraA [araA] ) was the first antiviral agent licensed in the United States for systemic use against herpes infections. Despite its proven clinical efficacy (21, 39) , the details of its mechanism of action remain sparse. Although many of the biochemical studies addressing the mechanism of action of araA have advanced the notion that the viral DNA polymerase is an ultimate target of the drug (3, 13, 25, 28, 30, 33) , conceivably, other enzymes could also serve as targets (for review, see references 14 and 27).
A definite role for the viral DNA polymerase in mediating susceptibility to araA has been posited on the basis of a study of herpes simplex virus (HSV) mutants resistant to araA (8) . Several mutants were isolated for resistance to araA; selection for araA resistance also selected for resistance to phosphonoacetic acid (PAA), an established marker for the HSV DNA polymerase (pol) locus (4-6, 12, 16, 20, 23, 24, 29) . Additionally, a mutant previously isolated for PAA resistance, PAAr5 (24) , was found to be resistant to araA. The araA resistance and PAA resistance markers of this mutant were shown to be closely linked; moreover, the mutant specified HSV DNA polymerase activity which exhibited a higher Ki for araATP (8) . These findings have been extended in a study mapping the araA and PAA resistance markers of PAAr5 to a 1.1-kilobase-pair (kbp) fragment in the pol locus (6) and in a report mapping an araA resistance marker from another mutant to a 2.6-kbp fragment in the pol locus (11) . These studies led to the conclusions that araA acts selectively on HSV and that the DNA polymerase is a target of araA action (8) .
Recently, several mutants isolated for resistance to phosphonoformic acid (PFA) (12), a congener of PAA, were found to be resistant to araA (2). However, when an inhibitor of adenosine deaminase, deoxycoformycin (pentostatin, covidarabine [DCF] ) (40) , was included with the araA, it was reported that resistance was abolished (2). These findings, along with kinetic analyses of the mutant polymerases, were used both to support the conclusion that the araA resistance observed for previously described mutants (8, 31) other than the HSV DNA polymerase are probably important for the antiviral action of araA (2).
To address these questions, we have reexamined the araA-resistant mutants upon which previous conclusions implicating the HSV DNA polymerase as a target for this drug were based (6, 8) . We find that these mutants retain their resistance to araA in the presence of DCF. Moreover, this resistance can be mapped finely to an 0.8-kbp region in the HSV DNA polymerase locus, confirming that the HSV DNA polymerase is important for the antiviral action of araA.
MATERIALS AND METHODS Cells and viruses. African green monkey kidney cells (Vero cells) were propagated and maintained as described previously (38) . Viruses used included HSV type 1 wild-type strain KOS, mutants PAAr5 (6-8, 19, 24) , AraAr6, AraAr7, AraAr9, and AraArl3 (7, 8, 19) , and recombinant viruses P5PrBa8, P5PrKp3 (referred to as Ba8 and Kp3 in references 7 and 19), P5Aph+K2, and P5Aph+S1. The last two recombinant viruses were isolated after marker rescue experiments, using infectious PAAr5 DNA and fragments of wild-type strain KOS DNA and selection for restoration of wild-type levels of aphidicolin susceptibility (7) (see Fig. 2 for the map locations of the fragments used to construct the recombinant viruses).
Drugs. AraA was purchased from Calbiochem-Behring, LaJolla, Calif., and was prepared as described previously (8) . DCF ed virus was absorbed to cells in a volume of 0.1 ml of Dulbecco modified minimal essential medium containing 2% or more newborn calf serum for 1 h at 37°C in a humidified CO2 incubator, with gentle shaking every 15 min. After absorption, duplicate dishes of cells infected at each dilution were overlaid with 2% methylcellulose in Dulbecco modified minimal essential medium plus 2% serum containing the concentrations of the drugs indicated in the figures and text and then incubated at 37°C in a humidifed CO2 incubator. Plaques were visualized by neutral red staining 3 to 4 days postinfection and counted on the next day by illuminating the dishes from below. Only plaques visible to the naked eye were counted. RESULTS PAAr5 is resistant to araA and DCF. We reexamined the resistance to araA of PAAr5, a mutant derived from wildtype HSV type 1 strain KOS (24) . Previously, we analyzed araA susceptibility by plotting the log of the percent plaques remaining versus drug concentration, since differences between sensitive and resistant viruses could more easily be recognized in such a plot (8) . In this way, PAAr5 was first shown to be resistant to araA (8) . We have plotted the data in this report as percent plaques remaining on the ordinate versus the log of araA concentration on the abscissa to make our results directly comparable to those of Bastow et al. (2), who reported that resistance of certain mutants to araA was abolished when an adenosine deaminase inhibitor, DCF, was included. Figure 1A shows the results of a plaque reduction assay of KOS and PAAr5 at different concentrations of araA in the absence of DCF. Examination of the curves indicates a 50% effective dose (ED50; dose required to reduce plaque formation by 50%) of ca. 60 ,uM for strain KOS (similar to that reported by Bastow et al. [2] ) and an ED50 about threefold higher for PAAr5. These ED50 values are different from those reported by another group for these two viruses (11) or from those values which can be abstracted from When the relative susceptibilities of KOS and PAAr5 to araA were examined in the presence of 3.5 ,uM DCF (the dose used by Bastow et al.
[2]), we found that although DCF potentiated the antiviral effect of araA two-to threefold for both viruses, PAAr5 remained markedly resistant to araA in its presence (ED50, three-to fourfold greater than that of strain KOS) (Fig. 1B) . Importantly, virtually identical plaque reduction curves were obtained in the presence of either two-or fourfold greater concentrations of DCF. As has been previously reported (10, 26) , these concentrations of DCF displayed no detectable antiviral effect in the absence of araA (data not shown). The degree of the potentiation by DCF of the antiviral effect of araA for strain KOS which we observed was very similar to that observed by Bastow et al.
(2).
Other workers have also observed that PAAr5 is resistant to araA plus DCF (L. Schnipper and W. O'Brien, personal communications).
The marker conferring resistance to araA and DCF in PAA 5 maps to an 0.8-kbp sequence in the HSV pol locus. The marker conferring araA resistance in PAAr5 had previously been mapped to a 1.1-kbp DNA fragment in the HSV pol locus (6) . We wished to determine whether the mutation(s) Fig. 2 (6) . These viruses were as resistant to araA and 3.5 ,uM DCF as was PAAr5 (Fig; 1B) . These results map the marker for resistanc,e to araA and DCF in PAAr5 to the 1.1-kbp fragment (Fig. 2) .
To map this marker more finely, we used recombinant viruses constructed by marker rescue of PAAr5 from aphidicolin hypersensitivity to wild-type sensitivity by fragments of a recom'binant DNA plasmid containing wild-type sequences (7) . The map locations of the fragments used to construct these recombinant viruses, P5Aph+K2 and P5Aph+S1, are shown in Fig. 2 . These'recombinants display wild-type levels of susceptibility to PAA and aphidicolih (unpublished data). They al'so display wild-type levels of susceptibility to araA in the presence of 3.5 ,uM DCF (Fig.  1B) (22) , which span finely mapped pol mutations (6) and thus are good candidates to encode polymerase. The arrowheads denote the 3' ends of the transcripts. The map locations of the fragments used to construct the recombinant viruses used in the experiment depicted in Fig. 1 are shown as hatched boxes. The names of the recombinant viruses are indicated to the right of the boxes, and the viruses from which the DNA fragments used to construct the recombinants were derived are within parentheses. At the bottom of the figure are two black boxes; the upper box depicts the previous map limits for the araAr marker of PAA'5 (6), and the bottom box indicates the map limits from the experiment depicted in Fig. 1 PAA'5 maps to the 0.8-kbp DNA sequence, which the fragments used to construct the recombinants overlap (map coordinates, 0.427 to 0.432).
Resistance of mutants selected for araA resistance to araA and DCF. We tested several of the mutants which had been isolated for resistance to araA in the absence of DCF (8) Fig. 3 . The curves for the other two mutants fall between those of AraAr9 and AraAr13 (data not shown). These mutants, then, exhibit ED50s two-to threefold greater than that of strain KOS. Thus, their selection for araA resistance was not due to the omission of an adenosine deaminase inhibitor.
DISCUSSION
Our results clearly demonstrate that HSV mutants can be isolated which are resistant to araA in the presence of 3.5 ,uM DCF, an inhibitor of adenosine deaminase. We believe that in our experiments adenosine deaminase was, in fact, inhibited for the following reasons: (i) 3.5 ,uM DCF has been shown to completely inhibit the deamination of araA in a monkey kidney cell line (9, 37) adenosine deaminase has been reported to be at least five orders of magnitude lower than the concentration we used (1); (iii) the antiviral effect of araA was potentiated by DCF to the extent reported by others (2, 10); and (iv) increasing the DCF concentration fourfold did not increase the potentiating effect. Nevertheless, we still observed araA resistance in the mutants studied ( Fig. 1 and 3) . Thus, it is highly unlikely that the araA resistance which we observed reflects decreased susceptibility to araHx (2). Rather, it appears to be due to araA itself. It should be noted that HSV strains which were more resistant than other strains to araA in the presence of DCF were described by Connor et al. in 1975 (10) .
The results of our mapping experiments refine the map limits for the mutation(s) conferring araA resistance in mutant PAAr5 to an 0.8-kbp region within the pol locus (Fig.  2) . DNA sequencing studies are under way to determine the amino acid changes which result in the araA resistance phenotype. The data reported here combined with the previous report that PAAr5 specifies DNA polymerase with a higher Ki for araATP than that of wild-type-specified polymerase (8) confirm that alterations in HSV DNA polymerase can result in resistance to araA. Thus, HSV polymerase is clearly a determinant of araA susceptibility.
Similarly, mutants which had been selected for resistance to araA retained resistance to araA in combination with DCF (Fig. 3) . The phenotypes of these mutants seem likely to be due to mutations in the pol locus, based on their susceptibilities to other drugs (7, 8; Coen et al., manuscript in preparation), their antimutator phenotypes (19) It is intriguing that mutants such as those described by Bastow et al. (2) could be resistant to araA alone and not to araA and DCF. This would tend to counter suggestions (14, 27, 34) that the antiviral effects of araHx are due to conversion of araHx-monophosphate to araAMP by sequential action of the enzymes adenylosuccinate synthetase and adenylosuccinate lyase (35, 36) . This also suggests that resistance of pol mutants to nucleoside analogs that are altered in their sugar moiety can depend absolutely on the nature of the base moiety as well. As yet, we have observed quantitative differences in the degree of resistance of various mutants to analogs which differ in this fashion but no qualitative differences (Coen et al., manuscript in preparation). Nevertheless, there is considerable variation among HSV pol mutants with respect to araA resistance, even among those which are resistant to PAA or PFA or both. For example, PAAr5 has been reported to be more resistant to araA than are other araA-resistant mutants (8, 11 ; this report), whereas other PAAr mutants have been reported to be sensitive to araA (6, 8, 16, 17 The isolation of araA-resistant mutants (8, 31) implies that araA acts selectively on HSV, and the mapping of resistance mutations to the pol locus implies that at least some of this selectivity resides in the HSV DNA polytnerase. One could hypothesize that the properties of the polymerase account for all of the selectivity. It is noteworthy that PAA'5 exhibits an ED50 three-to fivefold higher than that of its parental strain, KOS (8, 11; this communication). This difference is similar to the reported difference between the inhibition by araA of viral DNA synthesis in infected cells and cellular DNA synthesis in uninfected cells (32, 33 
